Basket trial health technology assessment requirements and limited access to innovations in oncology: The French paradox

Affiliations

• ¹ Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Oncostat U1018, Inserm, Université Paris-Saclay, Équipe Labellisée Ligue Contre le Cancer, Villejuif, France. Electronic address: [email protected].
• ² Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Early Phase Trials and Sarcoma Units, Department of Medical Oncology, Institut Bergonié, Bordeaux, France; University of Bordeaux, Bordeaux, France; SCOPP (French Academic Association for Early Phase Trial in Oncology), France; Société Française d'Immunotherapie des Cancers (FITC) France. Electronic address: [email protected].
• ³ Centre Eugène Marquis, Rennes, France; SCOPP (French Academic Association for Early Phase Trial in Oncology), France; Société Française d'Immunotherapie des Cancers (FITC) France. Electronic address: [email protected].
• ⁴ Department of Cancer Medicine, Léon Bérard Cancer Center, Lyon, France; SCOPP (French Academic Association for Early Phase Trial in Oncology), France; Société Française d'Immunotherapie des Cancers (FITC) France. Electronic address: [email protected].
• ⁵ Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; Société Française d'Immunotherapie des Cancers (FITC) France; INSERM U1015 & CIC1428, Universite Paris Saclay, Villejuif, France. Electronic address: [email protected].